Related references
Note: Only part of the references are listed.Topoisomerase IIα prevents ultrafine anaphase bridges by two mechanisms
Simon Gemble et al.
Open Biology (2020)
Integrating evolutionary dynamics into cancer therapy
Robert A. Gatenby et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
cGAS-STING and Cancer: Dichotomous Roles in Tumor Immunity and Development
Kevin W. Ng et al.
TRENDS IN IMMUNOLOGY (2018)
Chromosome missegregation during anaphase triggers p53 cell cycle arrest through histone H3.3 Ser31 phosphorylation
Edward H. Hinchcliffel et al.
NATURE CELL BIOLOGY (2016)
Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent
Ying Yi Chen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide
Catherine J. Drummond et al.
INVESTIGATIONAL NEW DRUGS (2011)
In vivo and in vitro assessment of the action of SN 28049, a benzonaphthyridine derivative targeting topoisomerase II, on the murine Colon 38 carcinoma
Ying Yi Chen et al.
INVESTIGATIONAL NEW DRUGS (2011)
Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes
F. Al-Ejeh et al.
ONCOGENE (2010)
Immunological aspects of cancer chemotherapy
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines
LW Deady et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Kinetic studies of the binding of acridinecarboxamide topoisomerase poisons to DNA: Implications for mode of binding of ligands with uncharged chromophores
LPG Wakelin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
The human decatenation checkpoint
PB Deming et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
